Joachim Rothe
Director/Board Member at Okairos AG
Network origin in Joachim Rothe first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
binx health, inc.
 binx health, inc. Information Technology ServicesTechnology Services Binx Health, Inc. develops and provides in vitro point-of-care (POC) testing on diseases such as sexually transmitted infections, neonatal sepsis and hospital acquired infections. Its technology products include in diagnostic and immunoassay platform, rapid POC, and nucleic acid detection technology. The company was founded by John Clarkson in 2005 and is headquartered in Trowbridge, the United Kingdom.
15
| Holding Company | Information Technology Services | 15 |
DNA Script SAS
 DNA Script SAS Medical SpecialtiesHealth Technology DNA Script engages in the provision of research and development in biotechnology. It manufactures synthetic deoxyribonucleic acid using enzymatic technology. The company was founded by Thomas Ybert, Sylvain Gariel and Xavier Godron in 2014 and is headquartered in Paris, France.
14
| Holding Company | Medical Specialties | 14 |
Cellerix SA
 Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa.
11
| Subsidiary | Pharmaceuticals: Generic | 11 |
Nouscom Srl
10
| Subsidiary | Miscellaneous Commercial Services | 10 |
Okairos AG
 Okairos AG Pharmaceuticals: MajorHealth Technology Okairos AG develops preventive and therapeutic vaccines against human chronic infectious diseases. Its products include genetic vaccines, adenovirus vector platform, and proprietary cell line. The company was founded by Riccardo Cortese, Alfredo Nicosia, and Antonella Folgori in 2007 and is headquartered in Basel, Switzerland.
10
| Subsidiary | Pharmaceuticals: Major | 10 |
Nouscom AG
 Nouscom AG Pharmaceuticals: MajorHealth Technology Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland.
10
| Holding Company | Pharmaceuticals: Major | 10 |
Binx Health Ltd.
 Binx Health Ltd. Miscellaneous Commercial ServicesCommercial Services Part of binx health, inc., Binx Health Ltd. is a British company that engages in research and development on biotechnology. The company is based in Trowbridge, UK. The company was founded in 2005. The CEO is Jeffrey R. Luber.
9
| Subsidiary | Miscellaneous Commercial Services | 9 |
Ariceum Therapeutics GmbH
 Ariceum Therapeutics GmbH Miscellaneous Commercial ServicesCommercial Services Ariceum Therapeutics GmbH is a German clinical stage radiopharmaceutical company that focuses on the diagnosis and precision treatment of certain neuroendocrine and other aggressive, hard-to-treat cancers. Ariceum Therapeutics is based in Berlin, DE, and has subsidiaries in various locations worldwide. The company's lead targeted systemic radiopharmaceutical product, -satoreotide tetraxetan ("satoreotide"), is an antagonist of the somatostatin type 2 (sstr2) receptor, which is overexpressed in neuroendocrine tumors (NETs) and some aggressive cancers such as small cell lung cancer (SCLC) and Merkel cell carcinoma. Ariceum is also developing a radiolabeled PARP-inhibitor (ATT-001), which is slated to enter the clinic in early 2024. The company was founded in 2021, and Manfred Rüdiger has been the CEO of the company since 2021.
8
| Holding Company | Miscellaneous Commercial Services | 8 |
LSP Services Deutschland GmbH
4
| Subsidiary | Investment Managers | 4 |
EQT Life Sciences (Munich)
1
| Subsidiary | Investment Managers | 1 |
Morphochem AG
 Morphochem AG Miscellaneous Commercial ServicesCommercial Services Morphochem AG discovers and develops drugs. It focuses on finding therapeutic agents to treat cancer, anti-infectives, inflammation, metabolic disorders and infectious diseases, with particular emphasis on enzyme inhibitors. The company has developed an integrated chemical genomics drug discovery engine that it is applying in third party research programs and for building its own fully owned pipeline. Morphochem is headquartered in Munich, Germany.
1
| Subsidiary | Miscellaneous Commercial Services | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Joachim Rothe via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| ROCHE HOLDING AG | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| GENSIGHT BIOLOGICS S.A. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
F. Hoffmann-La Roche Ltd.
 F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| The American University of Rome | College/University | Undergraduate Degree Doctorate Degree Doctorate Degree Corporate Officer/Principal | |
| EXACT SCIENCES CORPORATION | Medical Specialties | Chief Executive Officer Chief Executive Officer Director/Board Member | |
| Instituto de Empresa SL | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| TIGENIX NV | Medical Specialties | Director/Board Member Director/Board Member Chief Executive Officer | |
| BIOTIE THERAPIES CORP | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
Reithera Srl
 Reithera Srl Real Estate Investment TrustsFinance ReiThera Srl is a contract development and manufacturing organization (CDMO) based in Rome, Italy. The Italian company specializes in technology and process development, as well as GMP manufacturing, to support the clinical translation of genetic vaccines and medicinal products for advanced therapies. ReiThera has extensive expertise in developing scalable processes for viral-vector manufacturing and has a consolidated experience in GMP production of various types of viral vectors. The company's state-of-the-art facility includes bioreactors of different scales, a filling suite, and quality control laboratories. ReiThera's international team has contributed to several research projects aimed at unlocking the potential of innovative prophylactic and therapeutic programs. ReiThera Srl is dedicated to meeting the highest demand for the development, manufacture, and storage of viral vectors, drugs, and clinical samples. The company was founded in 2005 by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, and Stefano Colloca, who is also the CEO. | Real Estate Investment Trusts | Founder Chief Executive Officer Chief Executive Officer | |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Cardior Pharmaceuticals GmbH develops, manufactures and wholesales drugs. It focuses on the discovery, development and clinical validation of noncoding RNA therapeutics targeting microRNAs as medicines for patients with various forms of heart failure. The company was founded by Sandor Batkai, Claudia Ulbrich, and Thomas Thum on July 21, 2016 and is headquartered in Hannover, Germany. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| Harvard Business School | College/University | Undergraduate Degree Masters Business Admin Masters Business Admin | |
| THERADIAG | Medical Specialties | Director/Board Member Director/Board Member Director of Finance/CFO | |
| University of California, Berkeley | College/University | Undergraduate Degree Doctorate Degree Undergraduate Degree | |
| MOLECULAR PARTNERS AG | Biotechnology | Chairman Director/Board Member Director/Board Member | |
| APREA THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
Ipsen Bioinnovation Ltd.
 Ipsen Bioinnovation Ltd. BiotechnologyHealth Technology Ipsen Bioinnovation Ltd. Engages in the research and development of pharmaceutical products. The company was founded in 2005 and is headquartered in Abingdon, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
| Swiss Federal Institute of Technology | College/University | Doctorate Degree Doctorate Degree | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Massachusetts Institute of Technology | College/University | Doctorate Degree Undergraduate Degree | |
Mirvie, Inc.
 Mirvie, Inc. Medical SpecialtiesHealth Technology Mirvie, Inc. provides precise, actionable, non-invasive tests for maternal-fetal health. The company is headquartered in South San Francisco, CA. | Medical Specialties | Chairman Director/Board Member | |
T-Knife GmbH
 T-Knife GmbH BiotechnologyHealth Technology T-Knife GmbH operates as an next-generation adoptive T-cell company using its proprietary humanized T-cell receptor mouse platform to treat solid tumors. The company was founded by Thomas Blankenstein, Elisa Kieback and Holger Specht in 2018 and is headquartered in Berlin, Germany. | Biotechnology | Director/Board Member Director/Board Member | |
PathAI, Inc.
 PathAI, Inc. Packaged SoftwareTechnology Services PathAI, Inc. provides artificial intelligence powered technology for the pathology laboratory. It offers research and drug development, clinical and global health solutions. The firm specializes in pathology, digital pathology, oncology, immune-oncology, auto immune disease, neurodegenerative disease, companion diagnostics, precision medicine, solutions, research and development and computational pathology. The company was founded by Andrew H. Beck and Aditya Khosla in 2016 and is headquartered in Cambridge, MA. | Packaged Software | Director/Board Member Director/Board Member | |
| Université Catholique de Louvain | College/University | Doctorate Degree Graduate Degree | |
| SANOFI | Pharmaceuticals: Major | Corporate Officer/Principal Comptroller/Controller/Auditor | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Director/Board Member | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Corporate Officer/Principal Private Equity Investor | |
Biota Technology, Inc.
 Biota Technology, Inc. Miscellaneous Commercial ServicesCommercial Services Biota Technology, Inc. applies deoxyribonucleic acid (DNA) sequencing and data science to explore the earth's subsurface. It offers DNA data services for production profiling, sweet spot identification, and reservoir connectivity. The company was founded by Ajay Kshatriya and Rob Knight in 2013 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| University of Cambridge | College/University | Graduate Degree Masters Business Admin | |
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Investment Managers | Chairman Chief Operating Officer | |
| NANEXA AB | Medical Specialties | Chairman Director/Board Member | |
| VIVORYON THERAPEUTICS N.V. | Biotechnology | Director/Board Member Director/Board Member | |
| Yale University | College/University | Graduate Degree Doctorate Degree | |
| Technische Universität Braunschweig | College/University | Corporate Officer/Principal Undergraduate Degree | |
| 4SC AG | Biotechnology | Director/Board Member Chairman | |
ImCyse SA
 ImCyse SA BiotechnologyHealth Technology ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium. | Biotechnology | Director/Board Member Director/Board Member | |
Kymab Ltd.
 Kymab Ltd. Pharmaceuticals: MajorHealth Technology Kymab Ltd. discovers and develops human monoclonal antibody drugs. It is using mouse embryonic stem cell technology to develop its Kymouse platform that focuses on encompassing the diversity of the B lymphocyte component of the human immune system, and has the potential for expansion of diversity beyond the normal human immune response. Kymab was founded by Allan Bradley in 2009 and is headquartered in Cambridge, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
LSP Management Group BV
 LSP Management Group BV Investment ManagersFinance LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies. | Investment Managers | Corporate Officer/Principal Private Equity Investor | |
| Universidad Complutense de Madrid | College/University | Undergraduate Degree Undergraduate Degree | |
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| Universida de Alcalá de Henares | College/University | Doctorate Degree Undergraduate Degree | |
| ILLUMINA, INC. | Biotechnology | Corporate Officer/Principal Director/Board Member | |
Genetrix SL
 Genetrix SL BiotechnologyHealth Technology Genetrix SL develops biotechnological solutions. It is comprised of technology and biomedicine companies in order to maximize the value of the Group. The company was founded in May 20, 2003 and is headquartered in Madrid, Spain. | Biotechnology | General Counsel Chairman |
Statistics
International
| United States | 15 |
| Germany | 8 |
| Switzerland | 6 |
| France | 5 |
| Spain | 5 |
Sectoral
| Health Technology | 31 |
| Consumer Services | 12 |
| Finance | 6 |
| Commercial Services | 4 |
| Technology Services | 2 |
Operational
| Director/Board Member | 601 |
| Corporate Officer/Principal | 131 |
| Chairman | 110 |
| Independent Dir/Board Member | 102 |
| Chief Executive Officer | 78 |
Most connected contacts
| Insiders | |
|---|---|
| Eli Casdin | 48 |
| Heiner Dreismann | 46 |
| Philippe Peltier | 45 |
| Göran Albert Ando | 44 |
| Bradley Bolzon | 41 |
| Per Anders Göte Samuelsson | 36 |
| Jörg Neermann | 34 |
| Jean-Paul Prieels | 32 |
| Scott Rocklage | 32 |
| Nicholas Naclerio | 31 |
| Catherine Moukheibir | 29 |
| Florent Gros | 28 |
| David King | 27 |
| William Burns | 27 |
| Stanley Lapidus | 24 |
- Stock Market
- Insiders
- Joachim Rothe
- Company connections
